Tag: Pfizer

Categories
Health

C.D.C. Advisers Endorse Pfizer Vaccine for Youngsters Ages 12 to 15

C.D.C. Advisers Endorse Pfizer Vaccine for Children Ages 12 to 15

The federal government took one final step on Wednesday to bring Pfizer BioNTech coronavirus vaccine to teenagers in the United States, remove an obstacle to school reopening, and cheer millions of families tired of pandemic restrictions are.

An advisory committee of the Centers for Disease Control and Prevention voted The CDC director, Dr. Rochelle Walensky is expected to review the recommendations and approve them later on Wednesday.

“Getting Covid-19 vaccines approved for children ages 12-15 is an important step in removing barriers to vaccinating children of all ages,” said Dr. Yvonne Maldonado, who represents the American Academy of Pediatrics on the Federal Advisory Committee on Immunization Practices.

Many parents eagerly await the availability of vaccines for children, at least in part to expedite their return to school. About a third of eighth graders, usually 13 or 14 years old, still study completely remotely.

In some states, such as Maine, vaccination of teenagers has already started. Others plan to offer the vaccine as early as Thursday. There are nearly 17 million 12 to 15 year olds in the United States, which is 5.3 percent of the population.

Almost every state now has a flood of vaccine doses that could be quickly distributed to teenagers. The dose used to immunize adults is safe and effective for these adolescents too, as clinical studies have shown.

“Sometimes we lose the importance of children and adolescents in the midst of a pandemic – especially older adults are so much in focus,” said Dr. Grace Lee, Committee member and Professor of Pediatrics at Stanford University.

While the risk of serious illness in children is low compared to adults, the coronavirus has infected more than 1.5 million children and sent more than 13,000 to hospitals, according to the CDC, more than were hospitalized for flu in an average year

“It is currently one of the top ten causes of child death since the pandemic began,” noted Dr. Maldonado.

Young children are believed to be less likely to spread the virus than adults, but their ability to transmit it increases with age. Teenagers, especially in high school, can spread the virus just as easily as adults. Children aged 12-17 make up an increasing proportion of Covid cases in the country.

Vaccinating children should increase immunity levels in the US population and help reduce the number of cases.

“Any person with Covid-19 is giving the virus an opportunity to spread, further mutate and further expose our communities,” said Dr. Bill Gruber, Senior Vice President at Pfizer. “The decisions of the health authorities this week bring us one step closer to protecting young people and achieving herd protection.”

Pfizer announced in March that the vaccine appears to be at least as effective in 12-15 year olds as it is in older teenagers and adults. Apart from a slight increase in the frequency of fever, the shots also appeared to have comparable, mostly negligible side effects.

The company plans to monitor study participants for two years after the second dose to assess the long-term safety and effectiveness of the vaccine.

Updated

May 12, 2021, 4:58 p.m. ET

The Food and Drug Administration reviewed the clinical data and on Monday approved the Pfizer vaccine for use in these children. This allowed parents and children to wait weeks for a faster return to normal.

“While it is true that children are generally spared serious illnesses, the fact that they could not be vaccinated has created significant disruptions in their lives that have real developmental ramifications,” said Dr. Amesh Adalja, a senior scientist at the Johns Hopkins Center for Health Security. “By vaccinating this age cohort, these children can get back to their normal lives.”

In a speech at the White House on Wednesday, President Biden pointed out the benefits of the Covid vaccine for children 12 and older and said it was “safe, effective, easy, quick and free”.

“Starting tomorrow, more than 15,000 pharmacies will be ready to vaccinate this age group,” said Biden, adding that pharmacies would make it easier for teenagers to get the first shot in one location and a second shot in another location if needed.

Some experts have raised ethical concerns about vaccinating children who are at low risk for the virus, although healthcare workers and older adults remain at risk in many countries.

“If just thinking as a parent, if I had teenagers, I would probably love to vaccinate my children,” said Jennifer Nuzzo, an epidemiologist at the Johns Hopkins Center for Health Security.

Class disturbed

Updated May 5, 2021

The latest on how the pandemic is changing education.

But she added, “I am very concerned about a situation where the few countries in the world that had enough vaccines to protect their adults continue to hoard those vaccines for use in low-risk children.”

School reopenings have spiked across the country as parents, teachers, unions and school authorities worried about outbreaks. Research shows that children are largely spared serious illnesses and are not significant drivers of the spread of the coronavirus, as is the case with influenza.

“This misperception of risk will clearly divert vaccination priorities from the optimal strategic use of vaccines worldwide,” said Drs Adaliah.

The committee also recommended giving the Covid-19 vaccine along with other major vaccines that teenagers may have missed during the year. The agency had recommended waiting two weeks before and after immunization against Covid-19 before receiving other vaccines.

Parents’ reluctance can be the main hurdle. According to a recent survey by the Kaiser Family Foundation, more than 40 percent of parents of teenagers said that they would not vaccinate their children or would only vaccinate them if required by a school.

Some of these parents might change their minds as other children are safe to receive vaccines and resume personal schooling or return to team sports such as soccer and basketball that involve close contact, the researchers suggested.

Others can wait to meet school requirements. Public schools in all 50 states require certain vaccines, but officials may not be able to enforce compliance until the Pfizer BioNTech vaccine has received full FDA approval.

The vaccine now has an emergency approval. Pfizer has applied for full approval from the FDA, but this process is expected to take several months. Even after approval, students can opt out based on medical reasons or religious beliefs.

State and local leaders must make special efforts to reach children in low-income families or in color communities. Black and Hispanic adults have one of the lowest vaccination rates: by May 3, only 25 percent of blacks and 27 percent of Hispanics had been vaccinated, compared with 39 percent of whites.

In order to make the vaccine available to these communities, transport and storage of the cans must be facilitated. The Pfizer BioNTech vaccine can only be stored in standard refrigerators for five days. The companies plan to ship smaller packs for use in doctor’s offices and are developing a formulation that can be refrigerated for up to 10 weeks.

Pfizer and BioNTech plan to file applications for approval of the vaccine in children ages 2-11 in September.

Categories
Health

‘It’s a giant deal’ for America’s push to reopen, says NIH Director on Pfizer vaccine approval for adolescents

Pfizer and BioNTech begin the process of seeking full U.S. approval for their Covid vaccine

The director of the National Institutes of Health, Dr. Francis Collins, called the Food and Drug Administration approval for emergency use of Pfizer and BioNTech’s Covid vaccine for children ages 12-15 as “a big deal” in America’s drive to reopen.

“This is exciting news,” said Collins. “We know that since this pandemic started, one and a half million teenagers have been infected with Covid-19, and not all have been as good as most. And some of them have ended up where they have been with this long Covid We are not doing any better , even weeks or months after the illness, so we really want to protect young people. “

The Centers for Disease Control and Prevention’s Vaccine Advisory Board has scheduled a meeting on Wednesday to review recordings for children. If approved by the CDC as expected, it could be distributed to teens as early as this week.

More than 44% of all adults in the US are fully vaccinated, and according to the CDC, around 58% have now received at least one dose of the Covid vaccine. The White House aims to increase that number to 70% by July 4th.

Collins told CNBC’s “The News with Shepard Smith” that the US is “on a pretty good path” and that the nation should be able to see CDC regulations to relax indoor masks.

“It’s just about finding the right way to balance the desire not to create another wave. This is the last thing we need right now with the fact that people are really fed up with masks to wear, “said Collins.

Categories
Health

Pfizer and BioNTech start the method of searching for full U.S. approval for his or her Covid vaccine

Pfizer and BioNTech begin the process of seeking full U.S. approval for their Covid vaccine

Vials containing the Pfizer-BioNTech Covid-19 vaccine on Thursday, February 11, 2021 at the vaccination site of the Sun City Anthem Community Center in Henderson, Nevada, USA.

Roger Kisby | Bloomberg | Getty Images

Pfizer and German drug maker BioNTech announced that they have begun filing for full approval of their Covid-19 vaccine for people aged 16 and over in the United States. This makes the companies the first in the nation to apply for full regulatory approval.

The Food and Drug Administration issued emergency approval for their Covid vaccine at the end of December. Since then, Pfizer has distributed 170 million doses in the US, with the goal of having 300 million doses by the end of July.

“We are proud of the tremendous progress we have made in working with the US government to deliver vaccines to millions of Americans since December,” said Albert Bourla, Pfizer CEO, in a statement. “We look forward to working with the FDA to complete this ongoing filing and support its review with the aim of ensuring full regulatory approval for the vaccine in the months ahead.”

Pfizer needs to demonstrate that it can reliably manufacture the vaccines in order to get full clearance. If approved, companies could market their shots directly to consumers and potentially change the pricing of the cans. It also allows the shot to stay in the market once the pandemic is over and the US is no longer considered an “emergency”.

It usually takes the FDA about a year or more to determine whether a drug is safe and effective for the general public. Due to the once in a century pandemic that killed nearly 600,000 people in the United States, the FDA allowed the gunshots to be used as part of an emergency clearance.

The permit grants conditional approval based on data for two months. It’s not the same as a biological license application that requires six months of data and ensures full approval. Companies apply for approval on a “rolling filing” basis, which speeds the review process by allowing the FDA to review new data as soon as the company receives it.

“The BLA filing is an important cornerstone in achieving long-term herd immunity and future COVID-19 containment,” said Dr. Ugur Sahin, CEO and Co-Founder of BioNTech, in a statement. “We are excited to be working with US regulators to apply for approval of our COVID-19 vaccine based on our key Phase 3 study and follow-up data.”

Early data from 12,000 vaccinated people aged 16 and over in this Phase 3 study showed that the shots were 91.3% effective at getting the disease up for up to six months after the second dose and 95.3% effective against severe Covid as defined by the FDA. The companies said on April 1st. The data also showed “a favorable safety and tolerability profile,” they said at the time.

The companies are awaiting FDA emergency approval to use their vaccine in children ages 12-15 and intend to apply for a full license once they have six months of data.

They said in late March that the vaccine was 100% effective in a clinical study involving more than 2,000 adolescents. They also said the vaccine produced a “robust” antibody response in the children that outperformed that in a previous study in older teenagers and young adults. The side effects were generally consistent with those seen in adults, they added.

This is the latest news. Please try again.

Categories
Health

Pfizer Vaccine Is Extremely Efficient In opposition to Variants, Research Discover

Pfizer Vaccine Is Highly Effective Against Variants, Studies Find

The second new study, published in The Lancet, was carried out by researchers from the Israel Ministry of Health and Pfizer. It is based on more than 230,000 coronavirus infections that occurred in Israel between January 24th and April 3rd. During that period, B.1.1.7 accounted for nearly 95 percent of all coronavirus cases in the country, with more than half of which vaccinated its population.

The researchers found that the vaccine was more than 95 percent effective against coronavirus infections, hospitalizations, and deaths in people aged 16 and over who were fully vaccinated. It also worked well in older adults. Among those 85 years old or older, the vaccine was more than 94 percent effective against infection, hospitalization, and death.

As the percentage of people fully vaccinated increased in each age group, the incidence of coronavirus infections decreased in this cohort, the researchers found. The decline in infection rates was more in line with the timing of increases in vaccine coverage in each age group than the start of a nationwide lockdown. The results suggest that Israel’s rapid pace of vaccination was responsible for the decline in infections in the country.

“I’m just so happy to see this data that these vaccines have such an amazing impact on controlling infection and disease in the real world,” said Akiko Iwasaki, an immunologist at Yale University.

Both studies also reported that two doses of the vaccine provided significantly more protection than one dose. For example, in the Israel study, one dose of the vaccine was 77 percent effective against death, while two doses were 96.7 percent effective.

“It absolutely underscores the need for the second dose,” said Dr. Kathleen Neuzil, who directs the Center for Vaccine Development and Global Health at the University of Maryland School of Medicine.

Taken together, the studies suggest that vaccination remains a plausible way out of the pandemic even with the new variants, experts said. “If we can get vaccines out into the world and improve reporting,” said Dr. Neuzil, “I believe that we can go beyond that and stay up to date on the emergence of new variants.”

Categories
Health

Pfizer Will Search Approval to Give Covid Vaccine to Youngsters

Pfizer Will Seek Approval to Give Covid Vaccine to Children

Pfizer is expected to apply to the Food and Drug Administration for emergency clearance to administer its coronavirus vaccine to children ages 2-11 in September, the company told Wall Street analysts and reporters on Tuesday during its quarterly call for profits.

The company also plans to file for full approval of the vaccine this month for people ages 16 to 85. Clinical study data on the safety of his vaccine in pregnant women should be available by early August.

The Pfizer BioNTech vaccine will be given to adults as part of an emergency clearance the companies received in December. Obtaining full FDA approval would, among other things, enable the companies to commercialize the vaccine directly to consumers. The approval process is expected to take months.

“Full approval is a welcome indicator of the continued safety and effectiveness of the Pfizer vaccine,” said Saskia Popescu, an infectious disease epidemiologist at George Mason University, in an email. It could also “build further confidence in the importance of vaccination,” she said.

The Pfizer BioNTech coronavirus vaccine was the first to receive emergency approval in the United States. Emergency permits are temporary and can be revoked once a public health emergency has ended.

Full approval would allow the vaccine to stay in the market when the pandemic wears off. This can also make it easier for businesses, government agencies, schools, and other institutions to request a vaccination. For example, the University of California and California State University school systems have announced that after coronavirus vaccines are fully FDA approved, students, faculties, and staff will need to be vaccinated. The U.S. military, where many troops have turned down coronavirus vaccines, has said it wouldn’t make them mandatory as long as they only have an emergency permit.

The FDA is expected to issue emergency approval early next week to allow the vaccine to be used in children ages 12-15.

White House press secretary Jen Psaki said at a news conference Tuesday that she does not want to be ahead of the FDA but that the government is preparing to “make this available to additional, younger populations.”

Dr. Popescu said the opportunity to allow children in the United States to use the vaccine was both exciting and frustrating. “We have key people around the world who cannot get vaccines and countries that may not have access for a year or more, so we need to add global access to this conversation,” she said.

As of Tuesday, more than 131 million doses of the Pfizer BioNTech vaccine had been administered in the US, according to the Centers for Disease Control and Prevention. They make up just over half of all doses administered in the country to date.

Pfizer’s managing director, Dr. Albert Bourla said the company reached out to the FDA on Friday with new data to convince the agency that the vaccine can be stored at refrigerator temperatures and not frozen for up to four weeks. Currently the limit is five days. He said the company was working on an updated version of the vaccine that could potentially be refrigerated for up to 10 weeks and hoped to have supportive data for that by August.

Rebecca Robbins contributed to the coverage.

Categories
Politics

Pfizer Reaps Lots of of Hundreds of thousands in Income From Covid Vaccine

Pfizer Reaps Hundreds of Millions in Profits From Covid Vaccine

Several factors explain the inequality in Pfizer’s vaccine distribution.

The shot, which must be stored and transported at very low temperatures, is less practical for hard-to-reach parts of the world than other shots such as those from AstraZeneca and Johnson & Johnson that can simply be refrigerated. Some poor countries were not hit badly by the virus initially, so their governments had less urgency to place orders for the Pfizer vaccine as far as they could afford to pay for the shots.

“Not everyone was interested in the vaccine or willing to take steps. As a result, talks will continue, including working with Covax beyond the original 40 million cans, ”said Ms. Castillo, Pfizer spokeswoman.

In India, where the virus is spiraling out of control, the Pfizer vaccine is not used. The company applied for an emergency permit there, but withdrew the application in February because the Indian Medicines Agency was unwilling to waive the requirement to conduct a local clinical trial. At the time, India’s coronavirus case numbers were manageable and vaccines made locally were considered sufficient.

Pfizer and the Government of India have since resumed talks. On Monday, Mr Bourla said the company would donate more than $ 70 million worth of drugs to India and is trying to expedite vaccine approval.

Pfizer has made public promises to run its business not only for the enrichment of shareholders but also for the betterment of society.

Mr. Bourla, who earned $ 21 million last year, was among the 181 leaders of large companies who signed a 2019 Business Roundtable pledge to focus on a range of “stakeholders” including workers, suppliers and local communities – not just investors.

The financial numbers Pfizer reported Tuesday underestimate how much money the vaccine will generate. Pfizer is splitting its vaccine sales with BioNTech, which will publish its own first quarter results next week. BioNTech announced in March that it had achieved sales of nearly 10 billion euros, or around 11.8 billion US dollars, based on the vaccine orders it had ordered at the time.

Categories
Health

Pfizer expects aged, these with well being circumstances to be first

Pfizer expects elderly, those with health conditions to be first

A healthcare worker hands the Pfizer / BioNTech vaccine to Norman G. Einspruch, 88, a cardiology patient, on Dec. 30, 2020, as part of the COVID-19 vaccination schedule for seniors at Jackson Memorial Hospital in Miami, Florida, United States.

Marco Bello | Anadolu Agency | Getty Images

High-risk groups such as the elderly and those with underlying diseases are expected to be the first to receive booster shots of the Pfizer-BioNTech Covid-19 vaccine, the company’s chief scientist told investors on Tuesday.

The two-dose vaccine has been shown to be around 95% effective against Covid two weeks after the second dose, although researchers who helped develop the shot are now saying they are starting to see the strong protection with as time wanes.

Pfizer and BioNTech executives previously told CNBC that people will likely need a booster shot or third dose of the Covid-19 vaccine within 12 months of being fully vaccinated. They also said that people are likely to have to take extra shots every year.

During a call for earnings on Tuesday, Mikael Dolsten, Pfizer’s chief scientist, said it made sense to start with those who are most vulnerable, like older adults, and with chronic illnesses that make them more prone to serious illness and hospitalization like cardiovascular Diseases or cardiovascular diseases make asthma.

“We can’t predict what the CDC and FDA will do,” he added.

Dolsten’s comment comes after the company reported that the sale of its Covid-19 vaccine improved its first quarter financial results.

The company now expects total annual sales of the vaccine to be $ 26 billion, compared to its previous forecast of approximately $ 15 billion. Adjusted pre-tax profit in the high sales range of 20% is expected for the vaccine.

“Based on what we’ve seen, we believe continued demand for our Covid-19 vaccine, similar to that of the flu vaccines, is a likely outcome,” said Albert Bourla, CEO of Pfizer, to investors on the winning bid.

Should Americans need booster vaccinations, the US government would likely need to reach agreements with drug manufacturers to provide additional doses and make plans to distribute vaccines.

Last month Andy Slavitt, senior advisor to President Joe Biden’s Covid Response Team, said the White House was preparing for the potential need for Covid-19 vaccine booster shots. He said the Biden government was considering the need for extra doses.

Categories
Health

Pfizer PFE earnings Q1 2021

Pfizer's Covid vaccine approved by FDA for emergency use

A woman holds a small bottle that reads “Coronavirus COVID-19 Vaccine” and a medical syringe in front of the Pfizer logo displayed in this image dated October 30, 2020.

Given Ruvic | Reuters

Pfizer announced on Tuesday that it would apply to German drug manufacturer BioNTech for full US approval of its Covid-19 vaccine at the end of this month. If the FDA signs out, the company can market the shot directly to consumers.

When it released its first quarter financial results, the company reported first quarter sales of $ 3.5 billion on its Covid-19, generating profits and sales that exceeded Wall Street expectations.

According to Refinitiv’s average estimates, Pfizer has outperformed Wall Street expectations as follows:

  • Adjusted EPS: 93 cents per share compared to 77 cents expected
  • Revenue: $ 14.58 billion versus $ 13.51 billion expected

The company now expects total annual sales of the vaccine to be $ 26 billion, compared to its previous forecast of approximately $ 15 billion.

Pfizer shares rose 1.4% after the news.

This is a developing story. Please try again.

Categories
Health

FDA Set to Authorize Pfizer Vaccine for Adolescents by Early Subsequent Week

FDA Set to Authorize Pfizer Vaccine for Adolescents by Early Next Week

WASHINGTON – The Food and Drug Administration is preparing to approve the use of the Pfizer BioNTech coronavirus vaccine in adolescents ages 12-15 by early next week, according to federal officials familiar with the agency’s plans, and opens the US vaccination campaign to millions more people.

Some parents have counted down the weeks since Pfizer announced results of its teenage study showing the vaccine was at least as effective in this age group as it was in adults. Vaccinating children is key to increasing immunity in the population and reducing the number of hospitalizations and deaths.

The approval in the form of an amendment to the existing emergency approval for the Pfizer vaccine could come as early as later this week. If so, the Centers for Disease Control and Prevention’s vaccine advisory board is expected to meet the following day to review the clinical trial data and make recommendations on the use of the vaccine in adolescents.

The enlargement would be a major development in the country’s vaccination campaign and welcome news for some parents looking to protect their children during summer activities and before the start of the next school year. This is also another challenge for policy makers who have difficulty vaccinating a large percentage of adults who are reluctant to get the shot. Many more may refuse to vaccinate their children.

Pfizer reported a few weeks ago that none of the adolescents in the clinical trial who received the vaccine developed symptomatic infections, a sign of significant protection. The company said volunteers produced strong antibody responses and had roughly the same side effects seen in people aged 16-25.

Stephanie Caccomo, a spokeswoman for the Food and Drug Administration, said she was unable to comment at the time the agency made the decision.

“We can assure the public that we are working to look into this request as quickly and transparently as possible,” she said.

Over 100 million adults in the US have been fully vaccinated. However, approval would come in the middle of a delicate and complex push to reach the 44 percent of adults who have not yet received a single shot.

With much of the world demanding the surplus of US-made vaccines, the use of the Pfizer BioNTech shot in adolescents will also raise questions about whether care should be targeted at an age group largely spared heavy vaccines seems Covid19.

“I think we need to have a national and global conversation about the ethics of our vaccinated children, who are at low risk of serious complications from the virus, when there aren’t enough vaccines in the world to protect high-risk adults from dying “Said Jennifer B. Nuzzo, an epidemiologist at the Johns Hopkins Center for Health Security.

Updated

May 3, 2021, 8:53 p.m. ET

President Biden has come under increasing pressure to shed some of the country’s vaccine supplies. Some federal officials have also urged the government to decide soon how much vaccine is needed so that the doses do not expire or be shipped to the states and not used. The federal government has bought 700 million doses of three state-approved vaccines to be dispensed before the end of July, well in excess of what would be required for any American.

White House officials said last week that the intention is to make up to 60 million doses of the AstraZeneca vaccine available to other countries as long as federal regulators deem the doses to be safe. The vaccine has not yet been approved by American regulators. However, global health groups and public health experts said engagement was not enough.

Dr. Rupali J. Limaye, a Johns Hopkins University researcher investigating vaccine use and reluctance, said the United States should donate any surplus Pfizer BioNTech shots – and any surpluses from other manufacturers – to India and other countries that are had severe outbreaks and asked for help.

“From an ethical point of view, we shouldn’t give people like them priority over people in countries like India,” said Dr. Limaye about teenagers.

If the United States continues its supply of Pfizer-BioNTech, it should be reserved for adults while health officials grapple with the phase of the vaccination campaign that requires more individualized local contact.

“We still have to move past hesitant adults and start at the same time maybe 14 or 15,” said Dr. Limaye. “But the priority should still be adults.”

The current vaccine supply in the United States is substantial. As of Monday, about 65 million doses had been dispensed but not given, according to the CDC, including 31 million doses of the vaccine from Pfizer-BioNTech, nearly 25 million doses from Moderna, and 10 million doses from Johnson & Johnson

The Pfizer and Moderna vaccines each require two doses. Pfizer is approved for ages 16 and up, Moderna for ages 18 and over.

Dozens of millions more Pfizer BioNTech cans – about three weeks long, according to a federal official – have been made and are in various stages of readiness. They wait for the final tests before they are shipped.

Moderna expects results from its own clinical study in adolescents aged 12 to 17 years old soon, followed by results in children aged 6 months to 12 years later this year.

The approval of the Food and Drug Administration should ease the concerns of middle and high school administrators scheduled for the fall. If students can be vaccinated by then, it could lead to more normal gatherings and allow administrators to plan further ahead in the academic year.

Categories
Health

The Pfizer and Moderna vaccines are 94 % efficient at stopping hospitalization in older adults, a examine finds.

The Pfizer and Moderna vaccines are 94 percent effective at preventing hospitalization in older adults, a study finds.

Pfizer BioNTech and Moderna coronavirus vaccines prevent 94 percent hospitalization of fully vaccinated adults aged 65 and over, according to a small study published Wednesday by the Centers for Disease Control and Prevention.

The results, which are in line with clinical trial results, are the first real evidence from the US that the vaccines protect against severe Covid-19. Older adults are at the highest risk of being hospitalized and dying from the disease. More than 573,000 people have died from the virus across the country, according to a New York Times database. As of Wednesday, 142.7 million people had received at least one dose of one of three federally approved vaccines, including about 98 million people who were fully vaccinated.

“These results are encouraging and welcome news for two-thirds of people 65 and older who are already fully vaccinated,” said Dr. Rochelle Walensky, CDC director, in a statement. “Covid-19 vaccines are highly effective and these real world results confirm the benefits of clinical trials preventing hospitalizations among the most vulnerable.”

The study is based on data from 417 patients enrolled in 24 hospitals in 14 states between January 1 and March 26. About half were 75 years or older.

Both the Pfizer and Moderna vaccines require two shots three to four weeks apart. Older adults who were partially vaccinated – that is, received a dose of the vaccine more than two weeks earlier – were 64 percent less likely to be hospitalized with the coronavirus than unvaccinated seniors, the researchers reported.

The vaccines did not reduce hospitalization rates in people who received their first dose less than two weeks earlier. It takes time for the body to build an effective immune response, and people are considered fully vaccinated two weeks after the last dose in the series.

“This also underscores the persistent risk of serious illness shortly after vaccination, before a protective immune response has been achieved, and increases the need for vaccinated adults to continue physical distancing and prevention behaviors,” the scientists wrote.